Pfizer, the pharmaceutical giant known for its contribution to the fight against COVID-19, is making a strategic investment in obesity treatments. This move will be realized through a $4.9 billion acquisition of the development-stage drugmaker, Metsera.
Pfizer has agreed to pay $47.50 per share in cash for each Metsera share, reflecting a premium of over 42% to Metsera’s closing price on Friday. Moreover, Pfizer might extend an additional $22.50 per share contingent on the progress of Metsera’s product pipeline.
Also Consider Reading: Lawyers Claim Luigi Mangione Faces Possible Death Penalty ‘For Politics, Not Justice’
While Metsera has yet to bring a product to market, it has a robust pipeline with four programs in clinical development and one in mid-stage testing. This acquisition signifies Pfizer’s commitment to obesity treatments, a market that has experienced a significant surge in demand in recent years. This is largely due to the successes of market leaders such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy.
Pfizer currently has no obesity treatments available in the market. However, they have some in the clinical development stage. Earlier this year, Pfizer announced it was discontinuing the development of a potential once-daily pill treatment before it commenced late-stage testing, which is typically the most costly phase of clinical development.
Shares of Pfizer Inc., based in New York, increased by 31 cents to reach $24.33 before markets opened on Monday. Metsera’s stock also advanced, showing a rise of approximately 60%.
This acquisition indicates a strategic shift for Pfizer as it aims to capitalize on the growing demand for obesity treatments. It remains to be seen how these developments will affect the pharmaceutical landscape.
